Treatment of Autologous Hematopoietic Stem Cell Transplantation for Acute Leukemia: Historical Inheritance, System Construction and Optimization
CAO Jiaxin, PANG Aiming*, JIANG Erlie*
ASCT (autologous hematopoietic stem cell transplantation) is one of important post-remission treatments for AL (acute leukemia), especially in patients with low or moderate risk AML (acute myeloid leukemia) with CR1 (first complete remission), APL (acute promyelocytic leukemia) with CR2 (relapse and complete remission) or Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia). Meanwhile, MRD (minimal residual disease) status, conditioning regimens, maintenance treatment after transplantation and other factors are closely related to the prognosis of the diseases after ASCT. This article reviews the mechanisms and regulatory factors of the maintenance and self-renewal of HSCs (hemetopoietic stem cells). Besides, the research shares the diagnosis and treatment system and evaluation methods of ASCT established by the Institute of Hematology of the Chinese Academy of Medical Sciences and the Hematological Disease Hospital in order to promote the development and standardization of diagnosis and treatment strategies of ASCT in the treatment of AL, so as to improve the prognosis of patients with AL to the greatest extent
CN
EN